41
“Demyelinating” diseases Mark L Cohen, M.D. Department of Pathology University Hospitals Case Medical Center January 6 th , 2009

Pathology of Demyelinating Disease

Embed Size (px)

DESCRIPTION

 

Citation preview

Page 1: Pathology of Demyelinating Disease

“Demyelinating” diseases

Mark L Cohen, M.D.Department of Pathology

University Hospitals Case Medical CenterJanuary 6th, 2009

Page 2: Pathology of Demyelinating Disease

Learning Objectives

• Describe an algorithmic approach to the differential diagnosis of a patient with white matter disease.

• Provide examples of diseases representing the three major categories of leukoencephalopathies (genetic, acquired non-inflammatory & inflammatory) and discuss diagnostic features of each.

• Discuss the pathophysiology of Charcot’s triad, Uhthoff’s phenomenon, and L’hermitte’s symptom.

Page 3: Pathology of Demyelinating Disease

Normal myelinated axon

• Lipid-rich myelin sheath produced by oligodendrocytes• Axon insulation• Sodium channels clustered at nodes of Ranvier• Increased conduction speed and metabolic efficiency

Page 4: Pathology of Demyelinating Disease

Demyelination

• Decreased conduction velocity or block• Destablization of axonal cytoskeleton• Remodelling of internodal membrane• Progressive axonal loss

Page 5: Pathology of Demyelinating Disease

Oligodendroglial pathology

• Inborn errors– Leukodystrophies

• Acute injury– Inflammatory (multiple sclerosis and related

disorders)– Toxic and metabolic disturbances

• Chronic injury– Multiple system atrophy, progressive supranuclear

palsy

• Viral infection– Progressive multifocal leukoencephalopathy

• Neoplastic transformation– Oligodendrogliomas

Page 6: Pathology of Demyelinating Disease

Leukoencephalopathies: White matter damage with relative axonal preservation

• Inherited– Lipid, Protein, Mitochondrial,

Vascular• Acquired, non-inflammatory

– Toxic, Metabolic, Vascular, Traumatic

• Acquired, inflammatory– Infectious, Immunologic

Page 7: Pathology of Demyelinating Disease

MRI in Leukoencephalopathies

• Diffuse (Leukodystrophies)

• Discrete (Multiple sclerosis)

• Diverse (everything else)

Page 8: Pathology of Demyelinating Disease

Genetic disorders of white matter

• Lipid disorders (e.g. Adrenoleukodystrophy)• Cytoskeletal disorders (e.g. Alexander

disease)• Myelin protein disorders

(e.g Pelizaeus-Merzbacher disease)• Organic acid disorders (e.g Canavan disease)• Disorders of energy metabolism (e.g.

MELAS)

• Other (e.g. CADASIL)

Page 9: Pathology of Demyelinating Disease

Normal vs. Leukodystrophy (ALD)

Page 10: Pathology of Demyelinating Disease

Disease Cellular defect

Pathologic features

Metachromatic

Leukodystrophy

Lysosomal Metachromatic sulfatides within

macrophages

Krabbe Disease Lysosomal Globoid (multinucleated)

microglia

Adreno-

leukodystrophy

Peroxisomal Perivascular inflammation

Alexander disease

Cytoskeletal Rosenthal fibers

Page 11: Pathology of Demyelinating Disease

Subcortical U-fibers

Krabbe Disease Alexander Disease

Now you see ‘em Now you don’t

Page 12: Pathology of Demyelinating Disease

Globoid cell leukodystrophy (Krabbe)

Page 13: Pathology of Demyelinating Disease

Adrenoleukodystrophy

Alexander disease

Pelizaeus-Merzbacher Disease

Page 14: Pathology of Demyelinating Disease

Non-inflammatory Leukoencephalopathies

• Toxic (e.g. antineoplastic agents)• Metabolic (e.g. B12 deficiency)• Vascular (e.g hypertension)• Traumatic (e.g diffuse axonal injury)

Page 15: Pathology of Demyelinating Disease

Toxic leukoencephalopathies

• Structural alteration of white matter in which myelin suffers most

• Particularly involves tracts devoted to higher cerebral functioning

• Language usually preserved• Focal neurologic signs usually less

prominent than mental status changes

Page 16: Pathology of Demyelinating Disease

Radiation leukoencephalopathy

• Months to years after therapy (usually doses of 20 Gy or more)

• Vascular damage with hyalinization

• Coagulative necrosis of white matter

Page 17: Pathology of Demyelinating Disease

Central pontine myelinolysis Marchifava-Bignami disease

Page 18: Pathology of Demyelinating Disease

Inflammatory Leukoencephalopathies

• Infectious – HIV encephalitis– Progressive multifocal

leukoencephalopathy

• Immunologic – Multiple sclerosis & related disorders

Page 19: Pathology of Demyelinating Disease

HIV encephalitis

P24 immunostaining

Page 20: Pathology of Demyelinating Disease

Progressive multifocal leukoencephalopathy

Page 21: Pathology of Demyelinating Disease

Progressive multifocal leukoencephalopathy

JC virus immunostaining

Page 22: Pathology of Demyelinating Disease

Carswell, 1838

Babinski, 1885

Page 23: Pathology of Demyelinating Disease

1868

Nystagmus, intention tremor, scanning speech

Barber Chair phenomenon

Worsening of vision with exercise in optic neuritis

1890 1920

Page 24: Pathology of Demyelinating Disease

Site Symptoms Signs

Cerebrum Cognitive impairmentAttention deficit, dementia (late)

Optic Nerve Unilateral painful visual loss

Scotoma, afferent pupillary defect

CerebellumTremor

Clumsiness

Intention tremor

Ataxia, dysarthria

Brainstem Diplopia, vertigo, emotional lability

Nystagmus, INO, ophthalmoplegias

Spinal cordSpasms; bowel, bladder, erectile

dysfunctionSpasticity

Page 25: Pathology of Demyelinating Disease

• Reduced capacitance of thinly or unmyelinated axon segments underlies Uhthoff symptom

• Increased mechanical sensitivity of partially demyelinated axons underlies L’hermitte’s symptom

Page 26: Pathology of Demyelinating Disease

Clinical DDx of MS

• Systemic diseases with relapsing CNS involvement (vasculitis, collagen vascular disease, B12 deficiency)

• Progressive CNS system degenerations (hereditary ataxias, neuroaxonal dystrophies)

• Focal lesions with relapsing or progressive course (especially CNS tumors)

• Disseminated monophasic disorders (e.g. acute disseminated encephalomyelitis)

• Non-organic symptoms that mimic MS

Page 27: Pathology of Demyelinating Disease

MS Pathogenesis

•Molecular mimicry causes inappropriate migration of autoreactive myelin T cells across the blood-brain barrier, initiating an inflammatory reaction against proteins of the oligodendrocyte-myelin unit•T cells activated by IL-23 secrete IL-17, disrupting the blood-brain barrier•Th17 cells and activated microglia damage glia, axons, and neurons

Page 28: Pathology of Demyelinating Disease

Glia limitans perivascularis

Page 29: Pathology of Demyelinating Disease

2 steps to neuroinflammation

1 2

Glia limitans perivascularis

Post-capillary venule

Page 30: Pathology of Demyelinating Disease
Page 31: Pathology of Demyelinating Disease

Active demyelinating plaque

CD68 IHC

Page 32: Pathology of Demyelinating Disease

Gross pathology

Page 33: Pathology of Demyelinating Disease

Gross pathology

Page 34: Pathology of Demyelinating Disease

Inactive plaque

Page 35: Pathology of Demyelinating Disease

MS: Active & inactive plaques

Page 36: Pathology of Demyelinating Disease

Evolution of an MS plaque

Page 37: Pathology of Demyelinating Disease

Axonal pathology in MS

• Plaque associated axonal swellings (Charcot, 1880)

• More axons lost than generally believed (Marburg, 1906)

• Axonal sprouts arising from terminal spheroids (Jakob, 1915)

• Axonal transections in MS (Trapp et.al., NEJM, 1998)

• Nitric oxide donors produce reversible conduction block

• Prolonged NO causes NMDA receptor mediated toxicity

• Loss of oligodendroglial IGF1 support contributes to neuronal & axonal loss

Page 38: Pathology of Demyelinating Disease

Primary demyelination vs. primary neuroaxonal degeneration

Primary demyelination demonstrates:

• Lack of anatomic restriction

• Extension to pial surface

• Complete absence of myelin (occasionally with partial loss at interface secondary to remyelination)

Page 39: Pathology of Demyelinating Disease

MS: Recent advances

• Remyelination occurs in ~20% of people with MS, and is probably an important factor in re-establishing conduction

• Premyelinating oligodendrocytes are present in MS plaques

• In chronic MS plaques, persisting axons appear unreceptive to remyelination

Page 40: Pathology of Demyelinating Disease

Learning Objectives

• Describe an algorithmic approach to the differential diagnosis of a patient with white matter disease.

• Provide examples of diseases representing the three major categories of leukoencephalopathies (genetic, acquired non-inflammatory & inflammatory) and discuss diagnostic features of each.

• Discuss the pathophysiology of Charcot’s triad, Uhthoff’s phenomenon, and L’hermitte’s symptom.

Page 41: Pathology of Demyelinating Disease

References

• Compston A, Coles A. Multiple sclerosis. Lancet. 2008 Oct 25;372(9648):1502-17.

• Owens T, Bechmann I, Engelhardt B. Perivascular spaces and the two steps to neuroinflammation. J Neuropathol Exp Neurol. 2008 Dec;67(12):1113-21.